Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Retatrutide via Test vs Reference Device
NCT06003465Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of retatrutide in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration, Area Under the Plasma Concentration Versus Time Curve from Zero to Last Time Point and 1 more. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06003465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003465.